Gapping up
In reaction to earnings/guidance: VIPS +10.1%, ROX +6.7%, VDSI +6.1%, Z +4.2%, GT +4.2%, TTS +3.4%, QSR +2.7%, WM +2.7%, MDT +2.3%, ITRN +2.1%, GIS +1.1%, FDP +1.1%, HK +1%, USAT +0.5%
M&A news: CCG +5.6% (announces exploration of strategic alternatives), LMNS +1.5% (reports of Fosun (FOSUF) interest)
Select oil/gas related names showing early strength: GDP +3.9%, SDRL +3.9%, NBL +2.4%, PBR +1.9%, OAS +1.5%, WLL +1.3%, PWE +0.8%, BHI +0.8%
Other news: IBIO +40% (following 60 Minutes special this weekend on partner Mapp Pharma's ZMapp product as a treatment for Ebola), ONCY +29.4% (confims that the FDA has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of pancreatic cancer), GEVO +20.1% (cont strength), GENE +16.9% (cont pre-mkt vol), RXDX +7.1% (confirms it Received Orphan Drug Designation from FDA for Entrectinib for the Treatment of Molecularly Defined Subsets of Colorectal Cancer), CEL +6.5% (announces collective employment agreement), NAVB +5.6% (peer-reviewed publication of results from a Phase 3 clinical trial; results demonstrated that Lymphoseek met the primary efficacy endpoint), PSTI +5.2% (still checking), CYRN+4.6% (announced that ALSO Deutschland GmbH now distributes the cloud-based CYREN WebSecurity solution), CANF +3.6% (receives notice of allowance in U.S. for Psoriasis patent), MHR +3.4% (announces 2015 upstream capital expenditure budget; flexible 2015 upstream budget of $100 mln), RTK +3.2% (announces that GSO Capital Partners has increased its credit facility for Rentech by up to $63 million), CYTX +3% (announces the first patient has been treated in its FDA approved trial assessing the effect of Cytori Cell Therapy for osteoarthritis of the knee), NVAX +2.5% (favorable commentary on Friday's Mad Money), HOT +2.5% (announced that Frits van Paasschen has resigned as CEO), ACT +1.6% (launches generic Pulmicort RESPULES), NICE+1.4% (announces Sarit Sagiv as its new CFO), NEE +1.4% (announces CFO transition plan)
Analyst comments: SRPT +7.8% (upgraded to Buy from Neutral at BofA/Merrill), EURN +5.1% (initiated with a Buy at Citigroup), FEYE +1.5% (target raised to $49 from $44 at BofA/Merrill), GPRO +1.2% (initiated with a Outperform at Northland Capital), MU +1.1% (upgraded to Outperform from Neutral at Macquarie), BBVA +1% (upgraded to Outperform from Underperform at Exane BNP Paribas)
In reaction to earnings/guidance: VIPS +10.1%, ROX +6.7%, VDSI +6.1%, Z +4.2%, GT +4.2%, TTS +3.4%, QSR +2.7%, WM +2.7%, MDT +2.3%, ITRN +2.1%, GIS +1.1%, FDP +1.1%, HK +1%, USAT +0.5%
M&A news: CCG +5.6% (announces exploration of strategic alternatives), LMNS +1.5% (reports of Fosun (FOSUF) interest)
Select oil/gas related names showing early strength: GDP +3.9%, SDRL +3.9%, NBL +2.4%, PBR +1.9%, OAS +1.5%, WLL +1.3%, PWE +0.8%, BHI +0.8%
Other news: IBIO +40% (following 60 Minutes special this weekend on partner Mapp Pharma's ZMapp product as a treatment for Ebola), ONCY +29.4% (confims that the FDA has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of pancreatic cancer), GEVO +20.1% (cont strength), GENE +16.9% (cont pre-mkt vol), RXDX +7.1% (confirms it Received Orphan Drug Designation from FDA for Entrectinib for the Treatment of Molecularly Defined Subsets of Colorectal Cancer), CEL +6.5% (announces collective employment agreement), NAVB +5.6% (peer-reviewed publication of results from a Phase 3 clinical trial; results demonstrated that Lymphoseek met the primary efficacy endpoint), PSTI +5.2% (still checking), CYRN+4.6% (announced that ALSO Deutschland GmbH now distributes the cloud-based CYREN WebSecurity solution), CANF +3.6% (receives notice of allowance in U.S. for Psoriasis patent), MHR +3.4% (announces 2015 upstream capital expenditure budget; flexible 2015 upstream budget of $100 mln), RTK +3.2% (announces that GSO Capital Partners has increased its credit facility for Rentech by up to $63 million), CYTX +3% (announces the first patient has been treated in its FDA approved trial assessing the effect of Cytori Cell Therapy for osteoarthritis of the knee), NVAX +2.5% (favorable commentary on Friday's Mad Money), HOT +2.5% (announced that Frits van Paasschen has resigned as CEO), ACT +1.6% (launches generic Pulmicort RESPULES), NICE+1.4% (announces Sarit Sagiv as its new CFO), NEE +1.4% (announces CFO transition plan)
Analyst comments: SRPT +7.8% (upgraded to Buy from Neutral at BofA/Merrill), EURN +5.1% (initiated with a Buy at Citigroup), FEYE +1.5% (target raised to $49 from $44 at BofA/Merrill), GPRO +1.2% (initiated with a Outperform at Northland Capital), MU +1.1% (upgraded to Outperform from Neutral at Macquarie), BBVA +1% (upgraded to Outperform from Underperform at Exane BNP Paribas)